Preliminary study of [11C]methionine PET/CT in the diagnosis of IgG4 related disease

Preliminary study of [11C]methionine PET/CT in the diagnosis of IgG4 related disease - Preliminary study of [11C]methionine PET/CT in the diagnosis of IgG4 related disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019908

Enrollment

Registered

2016-01-01

Start date

2016-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgG4 related disease

Interventions

[11C]methionine PET/CT, [18F]FDG PET/CT

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) 20 y/o or older 2) Diagnosed as definite, probable or possible group of IgG4-related group by the Comprehensive Diagnostic Criteria for IgG4-Related disease 3) Before the treatment for IgG4-related disease by the administration of steroid 4) Written informed consent was acquired

Exclusion criteria

Exclusion criteria: 1) Pregnancy or possibility of pregnancy 2) Image acquisition by PET/CT is impossible due to the pain or poor performance status 3) Considered inadequate to attend this study by the researcher

Design outcomes

Primary

Measure	Time frame
1) Validation of [11C] methionine PET/CT images from the viewpoint of nuclear medicine physicians 2) Differences between [11C] methionine and [18F] FDG 3) Differences in the uptake between before and after treatment 4) Relevance to the PET uptake with clinical findings in the cases of treatment failure	—

Countries

Japan

Contacts

Public ContactTomohiko Yamane

Saitama Medical University International Medical Center Nuclear Medicine

yamane@mail.ne.jp042-984-4111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026